-
Mashup Score: 0Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 9 hour(s) ago
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 2 day(s) ago
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/koien4vJff
-
-
Mashup Score: 5
Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Through prolific biomarker research, @FAndreMD, has worked throughout his career to make strides in personalized breast cancer care. @GustaveRoussy @myESMO #bcsm #oncology https://t.co/MSoSTHWJI2
-
-
Mashup Score: 2Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer - 22 day(s) ago
Experts at the 2024 San Antonio Breast Cancer Symposium discussed knowledge gaps in understanding how best to use ribociclib in treating patients with early breast cancer in the adjuvant setting.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/koien4vJff
-
-
Mashup Score: 4NGS and Novel Therapies Lends to Prolonged Survival Outcomes in HR+/ HER2– Breast Cancer - 26 day(s) ago
Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Francisco J. Esteva, MD, PhD, discusses how NGS sequencing, PIK3CA-targeted therapies, and ADCs are reshaping treatment in HR+/HER2– breast cancer. @DrEsteva @NorthwellHealth #bcsm #oncology https://t.co/Y2zetM70mA
-
-
Mashup Score: 5
DETECT V tria data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer #bcsm #oncology https://t.co/WnQqjXgzT3
-
-
Mashup Score: 3
Adjuvant ribociclib plus endocrine therapy was approved in Europe for HR-positive/HER2-negative early breast cancer at high risk of recurrence.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer #bcsm #oncology https://t.co/i5A6B7clnI
-
-
Mashup Score: 5
DETECT V tria data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer #bcsm #oncology https://t.co/WnQqjXgzT3
-
-
Mashup Score: 6Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer - 1 month(s) ago
Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer. @MedicalCollege #bcsm #oncology Read more from Dr Chaudhary here: https://t.co/egNjjvDDlK
-
-
Mashup Score: 6Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer - 1 month(s) ago
Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer. @MedicalCollege #bcsm #oncology Read more from Dr Chaudhary here: https://t.co/egNjjvDDlK
-
Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer #bcsm #oncology https://t.co/koien4vJff